Skip to main content
. 2020 Mar 13;10:4662. doi: 10.1038/s41598-020-61688-7

Table 3.

Clinical, biological and immunohistochemical characteristics of sporadic colorectal cancer patients (n = 50) and their association with overall survival.

N Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Variable
Age
  <72 years 28 (55%) Ref. 0.7
  ≥72 years 23 (45%) 1.14 (0.56–2.31)
Gender
  Male 38 (76%) Ref. 0.9
  Female 13 (25%) 0.94 (0.40–2.18)
Site of primary tumor
  Colon 37 (73%) Ref. 0.8
  Rectum 14 (27%) 1.13 (0.48–2.66)
TNM stage at diagnosis
  StageI/II 27 (53%) Ref. <0.001* Ref.
  Stage III 4 (8%) 2.33 (1.29–4.21) 3.20 (0.67–15.14) 0.143
  Stage IV 19 (39%) 2.17 (1.60–2.94) 58.37 (8.66–393.62) <0.001*
Tumor size
  <4 cm 10 (20%) Ref. 0.9
  ≥4 cm 41 (80%) 1.05 (0.43–2.57)
CEA serum levels
  <5 ng 21 (48%) Ref. 0.008* Ref. 0.188
  ≥5 ng 23 (52%) 2.81 (1.28–6.16) 0.38 (0.09–1.61)
Microsatellite instability
  No 42 (84%) Ref. 0.8
  Yes 8 (16%) 1.12 (0.48–2.62)
EGFR
  <35% 36 (73%) Ref. 0.005* Ref. 0.044*
  ≥35% 13 (27%) 3.15 (1.36–7.33) 0.31 (0.10–0.97)
β-catenin
  Negative 29 (58%) Ref. 0.6
  Positive 21 (42%) 0.82 (0.39–1.72)
CEA
  Negative 11 (22%) Ref. 1
  Positive 39 (78%) 0.99 (0.45–2.16)
c-Myc
  <10% 9 (19%) Ref. 0.6
  ≥10% 39 (81%) 0.80 (0.32–1.96)
Her2
  Negative 49 (98%) NA NA
  3+ 1 (2%)
Ki-67
  <50% 34 (69%) Ref. 1
  ≥50% 15 (31%) 1.00 (0.45–2.20)
p53
  0 13 (26%) Ref. 0.7
  <10% 15 (30%) 1.36 (0.53–3.48)
≥10% 22 (44%) 0.99 (0.61–1.59)

Results expressed as number of cases (percentage). HR: hazard ratio. Ref.: reference group for HR calculation. *Statistically significant at p < 0.05. NA: not available, too few data elements in one group.

Stats for multivariant model: Concordance = 0.803 (se = 0.057); R2 = 0.495; Likelihood ratio test = 28.67 (p < 0.001); Wald test = 26.02 (p < 0.001); Score test = 37.55 (p < 0.001).